Abdominal infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:15:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Abdominal infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Aztreonam, Avibactam, and Metronidazole for Treating Infections in Neonates and Infants Under 9 Months with Gram-Negative Bacterial Infections https://clinicaltrials.eu/trial/study-on-aztreonam-avibactam-and-metronidazole-for-treating-infections-in-neonates-and-infants-under-9-months-with-gram-negative-bacterial-infections/ Wed, 29 Apr 2026 15:04:44 +0000 https://clinicaltrials.eu/trial/study-on-aztreonam-avibactam-and-metronidazole-for-treating-infections-in-neonates-and-infants-under-9-months-with-gram-negative-bacterial-infections/ This clinical trial is focused on studying infections caused by gram-negative bacteria in newborns and infants under 9 months old. These infections can include complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia, ventilator-associated pneumonia, sepsis, and bloodstream infections. The study will use a combination of medications called Aztreonam and Avibactam, with or without Metronidazole, to treat these infections. Aztreonam and Avibactam are antibiotics that work together to fight bacteria, while Metronidazole is another type of antibiotic that can be used to treat certain infections.

The purpose of this study is to learn more about how these medications work in the body, as well as to check their safety and how well they are tolerated by the infants. The study will be conducted in two parts, where the infants will receive either a single dose or multiple doses of the medications. The medications will be given through an intravenous infusion, which means they will be delivered directly into the bloodstream through a vein. The study will monitor the infants closely to see how their bodies process the medications and to watch for any side effects or reactions.

Throughout the study, researchers will collect information on how the medications affect the infants’ infections and overall health. This includes checking the levels of the medications in the blood, observing any side effects, and assessing the infants’ recovery from the infections. The study aims to provide valuable information that could help improve the treatment of serious bacterial infections in very young children.

]]> Study on High-Dose Short-Course Antibiotics for Critically Ill Patients with Pneumonia, Intra-Abdominal, or Bloodstream Infections: Ceftriaxone, Linezolid, and Cefotaxime https://clinicaltrials.eu/trial/study-on-high-dose-short-course-antibiotics-for-critically-ill-patients-with-pneumonia-intra-abdominal-or-bloodstream-infections-ceftriaxone-linezolid-and-cefotaxime/ Wed, 29 Apr 2026 15:04:34 +0000 https://clinicaltrials.eu/trial/study-on-high-dose-short-course-antibiotics-for-critically-ill-patients-with-pneumonia-intra-abdominal-or-bloodstream-infections-ceftriaxone-linezolid-and-cefotaxime/ This clinical trial is focused on studying the effectiveness of different antibiotic treatments for patients who are critically ill with serious infections. The diseases being studied include pneumonia, intra-abdominal infections, and bloodstream infections. The trial will compare a short course of high-dose antibiotics to the conventional dose and duration of treatment. The antibiotics being tested in this study are ceftriaxone, cefotaxime, cefuroxime, piperacillin-tazobactam, and meropenem. These medications are commonly used to treat bacterial infections and will be administered through intravenous (IV) methods.

The purpose of the study is to determine if a shorter, high-dose treatment is as effective as the traditional longer treatment in terms of patient survival over 90 days. The study will involve patients who are in the intensive care unit (ICU) and are expected to stay there for a certain period. During the trial, some patients will receive the short course, high-dose treatment, while others will receive the conventional treatment. The study will monitor various outcomes, including survival rates, the occurrence of new infections, and the overall health and recovery of the patients.

Participants in the study will be closely monitored for any side effects or complications. The trial aims to find out if the shorter treatment can reduce the exposure to antibiotics without compromising the effectiveness of the treatment. This could potentially lead to better management of antibiotic use in critically ill patients, helping to prevent the development of antibiotic resistance and improve patient outcomes.

]]> Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cefepime-nacubactam-and-aztreonam-nacubactam-for-adults-with-resistant-bacterial-infections/ Wed, 29 Apr 2026 15:00:18 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-cefepime-nacubactam-and-aztreonam-nacubactam-for-adults-with-resistant-bacterial-infections/ This clinical trial is focused on studying the effectiveness and safety of two treatment combinations for certain serious infections. The diseases being studied include complicated urinary tract infection, acute uncomplicated pyelonephritis (a type of kidney infection), hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and complicated intra-abdominal infection. These infections are caused by a group of bacteria known as carbapenem-resistant Enterobacterales, which are difficult to treat due to their resistance to many antibiotics.

The trial will compare the treatment combinations of cefepime/nacubactam and aztreonam/nacubactam against the best available therapy currently used for these infections. Cefepime and aztreonam are antibiotics, while nacubactam is a substance that helps these antibiotics work better against resistant bacteria. The study will involve administering these treatments through an intravenous infusion, which means the medication is given directly into a vein.

Participants in the study will receive one of the treatment combinations or the best available therapy for up to 14 days. The goal is to determine which treatment is most effective in achieving overall treatment success across all the infection types mentioned. The study will also monitor the safety of the treatments to ensure they are safe for use in patients. This trial aims to provide valuable information that could lead to better treatment options for these challenging infections.

]]> Study of Aztreonam-Avibactam and Metronidazole for Children with Serious Gram-Negative Bacterial Infections https://clinicaltrials.eu/trial/study-of-aztreonam-avibactam-and-metronidazole-for-children-with-serious-gram-negative-bacterial-infections/ Wed, 29 Apr 2026 14:24:59 +0000 https://clinicaltrials.eu/trial/study-of-aztreonam-avibactam-and-metronidazole-for-children-with-serious-gram-negative-bacterial-infections/ The study involves children from 9 months to under 18 years who have serious Gram-negative bacterial infections. These infections can appear as Hospital-acquired pneumonia, Ventilator-associated pneumonia, Complicated intra-abdominal infection, Complicated urinary tract infection, Bloodstream infection, or as Sepsis. The experimental treatment is a combination of Aztreonam-Avibactam given intravenous (through a vein), sometimes together with Metronidazole. Participants receive this new regimen or the best available therapy, which are the standard antibiotics normally used for these serious infections.

The purpose of the study is to evaluate the pharmacokinetics (PK) – how the medicine moves through the body – as well as safety and how well it is tolerated. Children will be treated for a short period, with blood samples taken to check drug levels and regular checks of liver and kidney function. After the treatment ends, follow‑up visits will assess whether the infection has cleared and whether any side effects occurred.

]]>